AU4611599A - Creation of Inventions and Patents with Artificial Intelligence

AU4611599A – Three-dimensional prostheses containing hyaluronic acid derivatives
– Google Patents

AU4611599A – Three-dimensional prostheses containing hyaluronic acid derivatives
– Google Patents
Three-dimensional prostheses containing hyaluronic acid derivatives

Download PDF
Info

Publication number
AU4611599A

AU4611599A
AU46115/99A
AU4611599A
AU4611599A
AU 4611599 A
AU4611599 A
AU 4611599A
AU 46115/99 A
AU46115/99 A
AU 46115/99A
AU 4611599 A
AU4611599 A
AU 4611599A
AU 4611599 A
AU4611599 A
AU 4611599A
Authority
AU
Australia
Prior art keywords
hyaluronic acid
matrix
dimensional
prosthesis according
acid derivative
Prior art date
1998-06-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Application number
AU46115/99A
Other versions

AU761325B2
(en

Inventor
Lanfranco Callegaro
Andrea Pastorello
Marco Radice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Anika Therapeutics SRL

Original Assignee
Fidia Advanced Biopolymers SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1998-06-17
Filing date
1999-06-16
Publication date
2000-01-05

1999-06-16
Application filed by Fidia Advanced Biopolymers SRL
filed
Critical
Fidia Advanced Biopolymers SRL

2000-01-05
Publication of AU4611599A
publication
Critical
patent/AU4611599A/en

2003-06-05
Application granted
granted
Critical

2003-06-05
Publication of AU761325B2
publication
Critical
patent/AU761325B2/en

2019-06-16
Anticipated expiration
legal-status
Critical

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON

C08B—POLYSACCHARIDES; DERIVATIVES THEREOF

C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 – C08B35/00; Derivatives thereof

C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof

C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan

C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES

A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads

A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons

A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials

A61L15/28—Polysaccharides or their derivatives

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses

A61L27/14—Macromolecular materials

A61L27/20—Polysaccharides

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses

A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix

A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells

A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells

C—CHEMISTRY; METALLURGY

C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON

C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS

C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00

C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Abstract

The use of a three-dimensional prosthesis is described which is in the shape of a body part comprising at least one three-dimensional matrix having fibrous structure and containing a hyaluronic acid derivative. The prosthesis is used for reconstruction of human or animal body part.

Description

WO 99/65534 PCT/EP99/04167 1 THREE-DIMENSIONAL PROSTHESES CONTAINING HYALURONIC ACID DERIVATIVES PROCESS FOR THEIR PREPARATION Field of the Invention 5 The present invention describes three-dimensional prostheses and process for their preparation. Three-dimensional prostheses of the present invention can be used alone or in association with pharmaceutically or biologically active substances, and can be used as such or can act as scaffolds for cell cultures. Said three-dimensional io prostheses are useful for reconstruction of human or animal body part, surgery or neurosurgery Technical Background Prostheses intended for implant are usually made of synthetic materials or natural, treated materials. 15 Defects of the body walls, such as the abdominal walls, that cannot be repaired by autogenous tissues because of the extent of the trauma, may be treated, for example, with synthetic meshes. Indeed, the materials normally used for prostheses to reinforce or repair traumatised abdominal walls are tantalum gauze, stainless steel meshes, 20 polypropylene tissues, microporous e-PTFE, polygalactin 910, polyester, polyglycolic acid, cross-linked bovine pericardium. It has not, however, been possible to date to obtain satisfactory recovery of damaged tissue or impaired organs by implanting artificial prostheses such as cardiovascular or bone prostheses made of synthetic polymers or metals. 25 Indeed, these types of prostheses are prone to provoke inflammatory reactions in the host, they rarely integrate easily with the surrounding microenvironment, they cause the formation of fibroses and they are subject to mechanical wear and tear, thus requiring regular checks. One alternative is to transplant autologous tissues or organs, or more frequently 30 allogenic or even xenogenic ones. This solution has various disadvantages, such as immunogenic reactions, infections and the dearth of donors. Recently, a new biomedical practice known as tissue engineering has been WO 99/65534 PCT/EP99/04167 2 gaining ground. By this means, tissues similar to those of the organism can be obtained by taking cells by minor biopsies, expanding them in culture and cultivating them on biodegradable scaffolds. Such tissues, for example skin, cartilage and bone, are created in vitro and then grafted onto the patient (EP 5 0462426, WO 97/18842). Other tissues for which work is in progress to improve the reconstruction techniques are those of the visible parts or appendices of the human body such as the ears, nose, nipples, lips and breasts. It has proved particularly difficult, to date, to reconstruct the auricula because of io the difficulties linked with the anatomical location of the ear, where any asymmetries of size, shape or position are instantly noticeable. Moreover, it is difficult to reproduce the complex form of irregularly-shaped cartilage covered with skin. Various techniques are used to reconstruct the ear, according to the severity of 15 the trauma. In cases where only part of the ear has been severed, pieces of the same ear or the surrounding tissues are used to reconstruct the damaged part, or portions of intercostal cartilage are grafted into place and then covered with strips of adjacent skin, so that the implant can become vascularised. 20 When the auricula has been almost completely severed, synthetic auricular prostheses can be used. These have numerous disadvantages, however, such as the need for daily care, damage to the surrounding skin both on account of the direct contact with the prosthesis and because of the strong adhesives required to fix them in place. Some prostheses, however, are directly implanted into the bone. 25 Another reconstruction method consists in increasing the volume of tissue still available by means of expanders. Lastly, a very complex surgical technique is sometimes used that involves several steps carried out at different times, which gives acceptable results only after months of treatment. 30 Briefly, this technique consists in taking a portion of intercostal cartilage from the patient and shaping it into a form resembling the outer ear. The cartilage is usually first implanted subcutaneously on the forearm or back in order for it to become WO 99/65534 PCT/EP99/04167 3 vascularised, and is removed several times for reshaping. When the implant has reached a satisfactory stage of maturity, it is implanted in place of the ear and covered with a strip of adjacent skin. Lastly, the patient has to undergo further operations to improve the aesthetic 5 quality of the implant. Besides the disadvantage of having to perform so many different operations on the patient, this technique involves the use of intercostal cartilage which has different characteristics from that of the ear, such as its lesser elasticity. Unfortunately, these prostheses often do not take and degenerate to the point of 10 generalised necrosis and failure of the transplant or, more rarely, the cartilage may transform into bony tissue (calcification). The ideal material for such prostheses is therefore chemically inert, non carcinogenic, able to stand up to mechanical stress and able to be shaped into the desired form, sterilizable, not prone to physical modification by the tissue fluids, 15 they must not induce inflammatory, immunological, allergic or hypersensitivity reactions and they must not promote visceral adhesions (Jenkins S. D. et al. Surgery 94 (2); 392-398, 1983). Summary of the invention The present invention describes a three-dimensional prosthesis in the shape of a 20 body part comprising at least one three-dimensional matrix having an essentially fibrous or porous structure and containing at least one hyaluronic acid derivative, said prosthesis, when contains at least two of said three-dimensional matrixes, the first of said three-dimensional matrixes incorporating or being adhered to the second and possible further matrixes, said three-dimensional matrix(es) optionally 25 incorporating and/or being adhered to a bidimensional perforated matrix and containing a hyaluronic acid derivative. Said three-dimensional prostheses further comprise cells chosen from the group consisting of autologous or endogenous mature or mesenchymal cells, or complex systems of mesenchymal and different type of mature cell types. 30 Detailed description of the invention According to a preferred embodiment the prosthesis of the present invention comprises a matrix (A) selected from the group consisting of: WO 99/65534 PCT/EP99/04167 4 Al. A three-dimensional matrix having an essentially fibrous structure A2. A three-dimensional matrix having an essentially porous structure A3. A bidimensional perforated matrix said matrix (A) incorporating and/or being adhered to a matrix selected from the 5 group consisting of B. A three-dimensional matrix having an essentially porous structure in case (A) is (Al) or (A3) C. A three-dimensional matrix having an essentially fibrous structure in case (A) is (A2) or (A3) 10 D. A bidimensional perforated matrix in case (A) is (Al) or (A2) said matrix (A), (B), (C), (D) comprising at least one hyaluronic acid derivative. Of the hyaluronic acid derivatives to be used in the preparation of the three dimensional prostheses according to the present invention, the following are the ones of choice: 15 hyaluronic acid esters wherein a part or all of the carboxy functions are esterified with alcohols of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series (EP 0216453 B1 entirely incorporated by reference), especially with benzyl alcohol; cross-linked esters of hyaluronic acid wherein part or all of the carboxy groups are 20 esterified with the alcoholic functions of the same polysaccharide chain or of other chains (EP 0341745 BI entirely incorporated by reference); cross-linked compounds of hyaluronic acid wherein part or all of the carboxy groups are esterified with polyalcohols of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, generating cross-linking by means of spacer 25 chains (EP 0265116 B1 entirely incorporated by reference); hemiesters of succinic acid or heavy metal salts of the hemiester of succinic acid with hyaluronic acid or with partial or total esters of hyaluronic acid (WO 96/357207 entirely incorporated by reference); 0-sulphated derivatives (WO 95/25751 entirely incorporated by reference) or N 30 sulphated derivatives (PCT/EP98/01973 entirely incorporated by reference); quaternary ammonium salts, such as salts with tetrabutylammonium and phenyltrimethylammonium, of hyaluronic acid or a hyaluronic acid derivative WO 99/65534 PCT/EP99/04167 5 selected from the group consisting of N-sulphated hyaluronic acid, O-sulphated hyaluronic acid, the hemiesters of succinic acid with hyaluronic acid and optionally partially salified with heavy metals. The matrixes (Al) and (C) having an essentially fibrous structure contained in the 5 prostheses according to the present invention are preferably in the form of non woven tissue or in the form of meshes. The non woven tissue containing hyaluronic acid derivatives is prepared as described in US 5.520.916 we entirely incorporate herewith by reference. Such prostheses have the advantage of being made easily into any form, however 10 complex, and moreover according to the chemical structure of the hyaluronic acid derivative used and according to the degree of esterification have the advantage of having tensile strength and degradation times that can be adjusted according to the requirement of the area to be reconstructed. Said prostheses may also contain associations of natural, semisynthetic and 15 synthetic polymers. Natural polymers that can be used are, for example, collagen, coprecipitates of collagen and glycosaminoglycans, cellulose, polysaccharides in the form of gels such as chitin, chitosan, pectin or pectic acid, agar, agarose, xanthane, gellan, alginic acid or the alginates, polymannan or polyglycans, starch, natural gums. 20 The semisynthetic polymers, for example, can be chosen from the group consisting of collagen cross-linked with agents such as aldehydes or precursors of the same, dicarboxylic acids or their halogenides, diamines, derivatives of cellulose, hyaluronic acid, chitin, chitosan, gellan, xanthane, pectin or pectic acid, polyglycans, polymannan, agar, agarose, natural gum, glycosaminoglycans. 25 Lastly, examples of synthetic polymers that can be used are, for example, polylactic acid, polyglycolic acid or copolymers of the same or their derivatives, polydioxanes, polyphosphazenes, polysulphonic resins, polyurethanes, PTFE. As the prostheses according to the present invention are constituted by hyaluronic acid derivatives, they are able to stimulate tissue regeneration and cell growth on 30 their surfaces. Said prostheses, indeed, can be used as such or as scaffolds for cell cultures for the reconstruction of human or animal body parts which have been damaged or WO 99165534 PCT/EP99/04167 6 are missing following trauma or as a result of congenital defects. In the former case, the endogenous cells colonise the prosthesis in vivo, while in the latter case autologous cells are cultivated on the prosthesis before grafting. It is also possible to cultivate mature or mesenchymal cells that can be made to 5 differentiate into the desired cell line; complex systems of different cell types can also be cultivated. The prostheses according to the present invention may also contain pharmaceutically or biologically active substances, such as anti-inflammatory agents, antibiotics, growth factors, antimicotic, antimicrobial and antiviral agents. 10 Said products, alone or containing cell cultures, can be used in general, internal, otorhinolaryngological, plastic, aesthetic, oncological, orthopaedic, cardiovascular, gynaecological and abdominal surgery and neurosurgery The body parts that can be reconstructed by means of the prostheses are, for example, the auricula, the nose, the nasal septum, the pharynx, the larynx, the 15 trachea, joints such as the knuckles, the temporomandibular joints, bone structures and, moreover, eye sockets, cardiac valves, blood vessels, nipples, navels, internal organs and their parts and the secondary sexual organs. In the case of reconstruction of a human body part with a complex form such as the auricula, the product must meet the following requisites: 20 it must be of the same anatomical shape as the part to be reconstructed, and be of the correct size for the patient; it must have a surface on which the cells can multiply, adapting themselves to the form of the prosthesis; they must be biodegradable and at the same time guarantee that the structure of 25 the scaffold stays the same for as long as it takes for the new tissue to be formed. In order to produce at an industrial level prostheses with a complex form constituted by at least one hyaluronic acid derivative, that do not degrade rapidly when in contact with the body fluids or in cell culture solutions and that meet the above said requisites, it has been necessary to devise an innovative working 30 process by which to establish chemical-physical interactions between the molecules of the hyaluronic acid derivative, so that the prosthesis is firmly set in the desired form.
WO 99165534 PCT/EP99/04167 7 In particular when the matrix A is Al and said matrix incorporates matrix B, the process of the present invention comprises the following steps: -a) lining a mould with a layer of non woven tissue comprising a hyaluronic acid derivative 5 -b) impregnating said non woven tissue in the mould with an aqueous solution of a quaternary ammonium salt of hyaluronic acid or of a hyaluronic acid derivative such as O-sulphated hyaluronic acid or N-sulphated hyaluronic acid, the hemiesters of hyaluronic acid with succinic acid and optionally their salts with heavy metals 10 -c) freeze-drying the content of the mould thereby obtaining prostheses having the matrix Al incorporating the matrix B consisting of the ammonium salts for example, tetrabutylammonium salt of hyaluronic acid or phenyltrimethylammonium salt of hyaluronic acid, or of a hyaluronic acid derivative such as O-sulphated hyaluronic acid or N-sulphated hyaluronic acid, 15 the hemiesters of hyaluronic acid with succinic acid and optionally their salts with heavy metals. -d) optionally converting the ammonium salt contained in the prostheses coming from step (c) into a hyaluronic acid derivative selected from partial or total ester of hyaluronic acid with alcohols of the aliphatic, aromatic, arylaliphatic, 20 cycloaliphatic or heterocyclic series, crosslinked esters of hyaluronic acid wherein part or all of the carboxy groups are esterified with alcoholic functions of the same or a different polysaccharide chain or other chains, crosslinked derivative of hyaluronic acid, wherein part or all of the carboxy groups are esterified with polyalcohols of the aliphatic, aromatic, arylaliphatic, 25 cycloaliphatic or hetherocyclic series generating crosslinking by means of spacer chains, hemiester of succinic acid or heavy metal salt of hemiester of succinic acid with partial or total ester of hyaluronic acid, N-sulphated or 0 sulphated partial or total ester of hyaluronic acid. -e) optionally freeze drying the product coming from (c); 30 When the matrix A is A2 or the product obtained from above defined step c or d of the preceding process and is adhered to matrix C, the process comprises the following steps: WO 99/65534 PCT/IEP99/04167 8 -a’) applying a thin layer of an aqueous solution of a quaternary ammonium salt of hyaluronic acid or of a derivative selected from O-sulphated hyaluronic acid (WO 95/25751) or N-sulphated hyaluronic acid (PCT/EP98/01973), hemiesters of hyaluronic acid with succinic acid and optionally their salts with heavy metals 5 (W096/357207) to the same or a different freeze-dried quaternary ammonium salt -b’) adhering to the mixture coming from step (a’) a layer of non woven tissue comprising a hyaluronic acid derivative -c’) freeze-drying the mixture coming from step (b’) thereby obtaining prostheses 10 wherein the matrix A is A2 and consists of an ammonium such as quaternary ammonium salt of hyaluronic acid or of a derivative thereof which has not yet been esterified such as O-sulphated hyaluronic acid (WO 95/25751) or N sulphated hyaluronic acid (PCT/EP98/01973), the hemiesters of hyaluronic acid with succinic acid and optionally their salts with heavy metals (W096/357207) 15 adhering to the matrix C -d’) optionally converting the ammonium salt contained in the prostheses coming from step (c’) with a hyaluronic acid derivative selected from partial or total ester of hyaluronic acid with alcohols of the aliphatic, aromatic, arylaliphatic, cycloaliphatic or heterocyclic series, crosslinked esters of hyaluronic acid 20 wherein part or all of the carboxy groups are esterified with alcoholic functions of the same or a different polysaccharide chain or other chains, crosslinked derivative of hyaluronic acid, wherein part or all of the carboxy groups are esterified with polyalcohols of the aliphatic, aromatic, arylaliphatic, cycloaliphatic or heterocyclic series generating crosslinking by means of spacer 25 chains, hemiester of succinic acid or heavy metal salt of hemiester of succinic acid with partial or total ester of hyaluronic acid, N-sulphated or O-sulphated partial or total ester of hyaluronic acid -e) optionally freeze drying the product coming from (d’); and When matrix (A) is (A2) or the product obtained from above defined step c or d 30 coming from the first process and is adhered to matrix (C), the process comprises the following steps: -a”) applying a thin layer of a solution of a hyaluronic acid derivative in a suitable WO 99165534 PCTIEP99/04167 9 aqueous or organic solvent, such as DMSO, said hyaluronic acid derivative being selected from partial or total ester of hyaluronic acid with alcohol of the aliphatic, aromatic, arylaliphatic, cycloaliphatic or heterocyclic series, crosslinked esters of hyaluronic acid wherein part or all of the carboxy groups 5 are esterified with alcoholic functions of the same or a different polysaccharide chain or other chains, crosslinked derivatives of hyaluronic acid, wherein part or all of the carboxy groups are esterified with polyalcohols of the aliphatic, aromatic, arylaliphatic, cycloaliphatic or heterocyclic series generating crosslinking by means of spacer chains, hemiester of succinic acid or heavy 10 metal salt of hemiester of succinic acid with partial or total ester of hyaluronic acid, N-sulphated or O-sulphated partial or total ester of hyaluronic acid -b”) applying a non woven tissue comprising a hyaluronic acid derivative to the freeze dried product coming from step (a”) -c”) freeze-drying the product coming from step (b”). 15 In case the prosthesis according to the present invention contains at least one porous matrix consisting of a hyaluronic acid derivative, the process comprises the following steps: a”‘) pouring an aqueous solution of a quaternary ammonium salt of hyaluronic acid or of a derivative selected from O-sulphated hyaluronic acid, N-sulphated 20 hyaluronic acid and hemiesters of hyaluronic acid with succinic acid and optionally their salts with heavy metals into a mould having the shape of the body part to be reconstructed b”‘) freeze drying the aqueous solution in the mould c'”) detaching the freeze dried product from the mould and converting the freeze 25 dried ammonium salts into at least one hyaluronic acid derivative selected from partial or total ester of hyaluronic acid with alcohols of the aliphatic, aromatic, arylaliphatic, cycloaliphatic or heterocyclic series, crosslinked esters of hyaluronic acid wherein part or all of the carboxy groups are esterified with alcoholic functions of the same or a different polysaccharide chain or other 30 chains, crosslinked derivative of hyaluronic acid, wherein part or all of the carboxy groups are esterified with polyalcohols of the aliphatic, aromatic, arylaliphatic, cycloaliphatic or heterocyclic series generating crosslinking by WO 99/65534 PCTIEP99/04167 10 means of spacer chains, hemiester of succinic acid or heavy metal salt of hemiester of succinic acid with partial or total ester of hyaluronic acid, N sulphated or 0-sulphated partial or total ester of hyaluronic acid d”‘) freeze drying the product coming from the preceding step in the mould 5 Example 1 Preparation of the phenyltrimethylammonium salt of hyaluronic acid Sixty-nine grams of sodium hyaluronate is solubilised in 4 I of water and passed through a column previously filled with Dowex Resin M15 in tetrabutylammonium form. This is freeze-dried, after which 100 g of hyaluronic acid 10 tetrabutylammonium salt is obtained. One hundred and fifty grams of hyaluronic acid tetrabutylammonium salt (HA TBA) and 225 g of phenyltrimethylammonium chloride are solubilised in a mixture constituted by 2 I of water and 3 1 of acetone (40/60 mixture). Fifteen litres of acetone are added and a precipitate of hyaluronic acid 15 phenyltrimethylammonium salt is obtained. The precipitate is washed several times with acetone and dried at a temperature of about 350C for 72 hours (Yield: 125 g). Example 2 Preparation of a prosthesis for the reconstruction of the auricula constituted by the 20 total benzyl ester of hyaluronic acid (HYAFF@1 1) A hollow mould is prepared in the shape of the auricula, made of polymers used in dentistry. The shape of the missing ear is reconstructed by a computerised system using a mirror image of the other ear. The mould is lined with a layer of HYAFF@1 1 in the form of a non-woven tissue, 25 fitting it closely to the shape of the mould. The non-woven tissue is impregnated with 15 ml of an aqueous solution of hyaluronic acid salt with phenyltrimethylammonium at a concentration of 70 mg/ml and this is freeze-dried. The solid intermediate product in the form of an auricula, constituted by the salt of 30 hyaluronic acid with phenyltrimethylammonium, that contains the non-woven HYAFF@1 I tissue, is removed from the mould and exposed to an esterification reaction in the heterogeneous phase.
WO 99/65534 PCTIEP99/04167 11 The material is placed in 0.3 litres of acetone per gram of intermediate product, and then 4 grams of tetrabutylammonium bromide and 3 ml of benzylbromide are added. The mixture is kept at boiling point for 12 hours. The product is repeatedly washed with a solution of ethanol and water in a ratio of 5 1:1 and containing 3% of sodium chloride, after which it is washed with water. Lastly, the product is put back into the mould and freeze-dried. Example 3 Preparation of a prosthesis for the reconstruction of the auricula constituted by the total benzyl ester of hyaluronic acid (HYAFF@11) 10 A hollow mould is prepared in the shape of the auricula, made of polymers used in dentistry. The shape of the missing ear is reconstructed by a computerised system using a mirror image of the other ear. The mould is lined with a layer of HYAFF@1 1 in the form of a non-woven tissue, fitting it closely to the shape of the mould. 15 The non-woven tissue is impregnated with 15 ml of an aqueous solution of hyaluronic acid salt with tetrabutylammonium at a concentration of 70 mg/mI and this is freeze-dried. The solid intermediate product in the form of an auricula, constituted by the salt of hyaluronic acid with tetrabutylammonium, that contains the non-woven 20 HYAFF@11 tissue, is removed from the mould and exposed to an esterification reaction in the heterogeneous phase. The material is placed in 0.06 litres of acetone per gram of intermediate product, and then 4.2 grams of tetrabutylammonium bromide and 1.4 ml of benzylbromide are added. 25 The mixture is kept at boiling point for 12 hours. The product is repeatedly washed with a solution of ethanol and water in a ratio of 1:1 and containing 3% of sodium chloride, after which it is washed with water. Lastly, the product is put back into the mould and freeze-dried. Example 4 30 Preparation of a prosthesis for the reconstruction of the auricula constituted by the total dodecyl ester of hyaluronic acid (HYAFF@11) WO 99/65534 PCT/EP99/04167 12 A hollow mould is prepared in the shape of the auricula, made of polymers used in dentistry. The shape of the missing ear is reconstructed by a computerised system using a mirror image of the other ear. The mould is lined with a layer of HYAFF@1 1 in the form of a non-woven tissue, 5 fitting it closely to the shape of the mould. The non-woven tissue is impregnated with 15 ml of an aqueous solution of hyaluronic acid salt with tetrabutylammonium at a concentration of 70 mg/ml and this is freeze-dried. The solid intermediate product in the form of an auricula, constituted by the salt of 10 hyaluronic acid with tetrabutylammonium, that contains the non-woven HYAFF@1 1 tissue, is removed from the mould and exposed to an esterification reaction in the heterogeneous phase. The material is placed in 0.06 litres of acetone per gram of intermediate product, and then 4.2 grams of tetrabutylammonium bromide and 1.4 ml of dodecyl 15 bromide are added. The mixture is kept at boiling point for 12 hours. The product is repeatedly washed with a solution of ethanol and water in a ratio of 1:1 and containing 3% of sodium chloride, after which it is washed with water. Lastly, the product is put back into the mould and freeze-dried. 20 Example 5 Preparation of a prosthesis for the reconstruction of the auricula constituted by the total benzyl ester of hyaluronic acid (HYAFF@1 1) in the form of a non-woven fabric incorporated in autocross-linked hyaluronic acid A hollow mould is prepared in the shape of the auricula, made of polymers used in 25 dentistry. The shape of the missing ear is reconstructed by a computerised system using a mirror image of the other ear. The mould is lined with a layer of HYAFF@11 in the form of a non-woven tissue, fitting it closely to the shape of the mould. The non-woven tissue is impregnated with 15 ml of an aqueous solution of 30 hyaluronic acid salt with tetrabutylammonium at a concentration of 70 mg/ml and this is freeze-dried.
WO 99/65534 PCT/EP99/04167 13 The solid intermediate product in the form of an auricula, constituted by the salt of hyaluronic acid with tetrabutylammonium, that contains the non-woven HYAFF@1 1 tissue, is removed from the mould and exposed to an esterification reaction in the heterogeneous phase. 5 The material is placed in 1.5 litres of acetone per 10 grams of intermediate product, and then 70 grams of molecular sieve and 10 g of 2-chloro-1-methyl pyridinium iodide are added. The mixture is kept at boiling point for 8 hours. The product is washed first with acetone and then with an aqueous solution 10 containing 3% sodium chloride and lastly with water. Example 6 Preparation of a three-dimensional prosthesis constituted by the total benzvl ester of hyaluronic acid (HYAFF@1 1) with a layer of non-woven fabric (HYAFF@ 11) adhered to its surface 15 Method 1 Adhesion of a layer of non-woven fabric (HYAFF@11) to the product before esterification A thin layer of a solution of hyaluronic acid salt with tetrabutylammonium in water at a concentration of about 70 mg/ml is applied onto the surface of a freeze-dried product constituted by hyaluronic acid salt with tetrabutylammonium or with 20 phenyltrimethylammonium, then a layer of non-woven fabric (HYAFF@1 1) is applied. The product is replaced in the mould, brought to a temperature of -40*C and freeze-dried. The product is then exposed to an esterification reaction, as in the previous examples. Method 1A The same method with the same ingredients described in 25 Method I is repeated without adding the layer of non woven fabric. Method 2 Adhesion of a layer of non-woven fabric (HYAFF@1 1) to the esterified product A thin layer of a solution of HYAFF@1 1 in dimethylsulfoxide (DMSO) at a 30 concentration of about 180 mg/ml is applied to the surface of the product constituted by HYAFF@1 1, after which a layer of non-woven fabric (HYAF@1 1) is applied. The product is then immersed in ethyl alcohol for at least 30 minutes. It is WO 99/65534 PCT/EP99/04167 14 then washed repeatedly with ethanol and then with water. The product is placed in the mould and freeze-dried. Cell culture on an auricular prosthesis A biopsy of nasal cartilage is taken by the standard procedure. 5 The specimen of cartilage is disintegrated by enzymatic digestion with 0.25% trypsin and 0.02% EDTA, incubated at 370C with 5% carbon dioxide for 15 minutes, followed by a second session of enzymatic digestion with a solution of 0.1% collagenase. The specimen is stirred and incubated for about 16 hours at 37 0 C. 10 Subsequently, any fragments of residue tissue are separated by centrifugation and the supernatant is removed. Enzymatic reaction is interrupted by adding culture medium enriched with 10% foetal bovine serum (FBS) or with Dulbecco’s minimal essential medium (DMEM) enriched with 10% FBS. 15 Approximately 1×10 6 /cm 2 of the cells are resuspended in a culture medium containing growth factors and seeded on the biomaterial in a dish measuring 100 mm in diameter. After three hours’ incubation at 370C, 10 ml of culture medium containing growth factor is added. The culture is incubated and fresh medium added 48 hours after 20 seeding and then every 48-72 hours. *** *** The invention being thus described, it is clear that these methods can be modified in various ways. Said modifications must not be considered as divergences from the spirit and purposes of the invention, and any modification that would appear 25 evident to an expert in the field comes within the scope of the following claims:

Claims (29)

1. A three-dimensional prosthesis in the shape of a body part comprising at least one three-dimensional matrix having an essentially fibrous or porous structure and containing at least one hyaluronic acid derivative, said prosthesis, when 5 contains at least two of said three-dimensional matrixes, the first of said three dimensional matrixes incorporating and/or being adhered to the second and possible further matrixes, said three-dimensional matrix(es) optionally incorporating and/or being adhered to a bidimensional perforated matrix and containing a hyaluronic acid derivative. 10

2. The three-dimensional prosthesis according to claim 1, comprising a matrix (A) selected from the group consisting of: Al. A three-dimensional matrix having an essentially fibrous structure A2. A three-dimensional matrix having an essentially porous structure A3. A bidimensional perforated matrix 15 said matrix (A) incorporating or being adhered to a matrix selected from the group consisting of B. A three-dimensional matrix having an essentially porous structure in case (A) is (Al) or (A3) C. A three-dimensional matrix having an essentially fibrous structure in case (A) is 20 (A2) or (A3) D. A bidimensional perforated matrix in case (A) is (Al) or (A2) said matrix (A), (B), (C), (D) comprising at least one hyaluronic acid derivative

3. The three-dimensional prosthesis according to claims 1-2, further comprising cells chosen from the group consisting of autologous or endogenous mature or 25 mesenchymal cells, or complex systems of mesenchymal and different type of mature cell types.

4. The three-dimensional prosthesis according to anyone of claims 1-3 further comprising natural, semisynthetic and synthetic polymers

5. The three-dimensional prosthesis according to claim 4, wherein the natural 30 polymers are chosen from the group consisting of collagen, coprecipitates of collagen and glycosaminoglycans, cellulose, polysaccharides in the form of gels such as chitin, chitosan, pectin or pectic acid, agar, agarose, xanthane, gellan, WO 99/65534 PCT/EP99/04167 16 alginic acid or the alginates, polymannan or polyglycans, starch, natural gums.

6. The three-dimensional prosthesis according to claim 4, wherein the semisynthetic polymers are chosen from the group consisting of collagen cross linked with agents such as aldehydes or precursors of the same, dicarboxylic 5 acids or the halogenides thereof, diamines, derivatives of cellulose, hyaluronic acid, chitin or chitosan, gellan, xanthane, pectin or pectic acid, polyglycans, polymannan, agar, agarose, natural gum and glycosaminoglycans.

7. The three-dimensional prosthesis according to claim 4, wherein the synthetic polymers are chosen from the group consisting of polylactic acid, polyglycolic 10 acid or copolymers of the same or their derivatives, polydioxans, polyphosphazenes, polysulphonic resins, polyurethanes, PTFE.

8. The three-dimensional prosthesis according to any one of claims 1-7, wherein at least one of said matrixes (A), (B), (C) and (D) consists of at least one hyaluronic acid derivative 15

9. The three-dimensional prosthesis according to claim 2, in which said matrix Al and C are selected from the group consisting of meshes or non woven tissue

10. The three-dimensional prosthesis according to any of claims 1-9, wherein the matrix (A2) and (B) are obtained by freeze drying process

11. The three-dimensional prosthesis according to claim 1, wherein said 20 bidimensional perforated matrix is obtained by perforating a bidimensional membrane having a continuous structure

12. The three-dimensional prosthesis according to any of claims 1-11, in which said hyaluronic acid derivative is chosen from the group consisting of esters of hyaluronic acid wherein part or all of the carboxy functions are esterified with 25 alcohols of the aliphatic, aromatic, arylaliphatic, cycloaliphatic or heterocyclic series.

13. The three-dimensional prosthesis according to claim 12, in which said hyaluronic ester is benzyl ester

14. The three-dimensional prosthesis according to any of claims 1-11, wherein the 30 hyaluronic acid derivative is chosen from the group consisting of cross-linked esters of hyaluronic acid wherein part or all of the carboxy groups are esterified with the alcoholic functions of the same or a different polysaccharide chain or WO 99/65534 PCT/EP99/04167 17 other chains.

15. The three-dimensional prosthesis according to any of claims 1-11, wherein the hyaluronic acid derivative is chosen from the group consisting of crosslinked compounds of hyaluronic acid wherein part or all of the carboxy groups are 5 esterified with polyalcohols of the aliphatic, aromatic, arylaliphatic, cycloaliphatic or heterocyclic series generating cross linking by means of spacer chains

16. The three-dimensional prosthesis according to any of claims 1-11, wherein the hyaluronic acid derivative is chosen from the group consisting of the hemiesters 10 of succinic acid or heavy metal salts of the hemiester of succinic acid with partial or total esters of hyaluronic acid.

17. The three-dimensional prosthesis according to any of claims 1-11, wherein the hyaluronic acid derivative is chosen from the group consisting of the partial or total esters of O-sulphated or N-sulphated derivatives. 15

18. The three-dimensional prosthesis according to any of claims 1-11, wherein the hyaluronic acid derivative is a quaternary ammonium salt of hyaluronic acid or a hyaluronic acid derivative selected from the group consisting of N-sulphated hyaluronic acid, 0-sulphated hyaluronic acid, the hemiesters of succinic acid with hyaluronic acid and optionally partially salified with heavy metals. 20

19. The three-dimensional prosthesis according to any of claims 1-18 in association with pharmaceutically or biologically active substances.

20. The three-dimensional prosthesis according to claim 19, wherein the pharmaceutically or biologically active substances are selected from the group consisting of anti-inflammatory agents, antibiotics, growth factors, antimicotics, 25 antimicrobials, antiviral agents.

21. The three-dimensional prosthesis according to any of claims 1-20 for reconstruction of human or animal body parts.

22. The three-dimensional prosthesis according to claim 21 wherein the body parts are the auricula, nose, nasal septum, pharynx, larynx, trachea, joints, 30 bone structures, eye socket, cardiac valves, blood vessels, nipple, navel, internal organs and their parts, the secondary sexual organs.

23. The three-dimensional prosthesis according to claim 21-22, wherein said body WO 99165534 PCT/EP99/04167 18 part is the auricula

24. The three-dimensional prosthesis according to claim 21-22, wherein said body part are knuckles or temporomandibular joint

25. The three-dimensional prosthesis according to any of claims 1-24 for use in 5 general, internal, otorhinolaryngological, plastic, aesthetic, oncological, orthopaedic, cardiovascular, gynaecological and abdominal surgery and neurosurgery

26. A process for preparing a three-dimensional prosthesis according to claim 2, wherein the matrix A is Al and said matrix incorporates matrix B, comprising 10 the following steps: -a) lining a mould with a layer of non woven tissue comprising a hyaluronic acid derivative -b) impregnating said non woven tissue in the mould with an aqueous solution of a quaternary ammonium salt of hyaluronic acid or a hyaluronic acid derivative as 15 defined in claim 18 -c) freeze-drying the content of the mould thereby obtaining prostheses having the matrix Al incorporating the matrix B consisting of the ammonium salts as defined in claim 18 -d) optionally converting the ammonium salt contained in the prostheses coming 20 from step (c) into a hyaluronic acid selected from those defined in claims 12-17 -e) freeze drying the product coming from (c)

27. A process for preparing a three-dimensional prosthesis according to claim 2, wherein the matrix A is A2 or it is the product of step (c) or (d) of the process according to claim 26 and is adhered to matrix C, comprising the following 25 steps: -a’) applying a thin layer of an aqueous solution of a quaternary ammonium salt as defined in claim 18 to the same or different freeze-dried quaternary ammonium salt as defined in claim 18 -b’) adhering to the mixture coming from step (a’) a layer of non woven tissue 30 comprising a hyaluronic acid derivative -c’) freeze-drying the mixture coming from step (b’) thereby obtaining prostheses wherein the matrix A is A2 and consists of an ammonium salt as defined in WO 99/65534 PCT/EP99/04167 19 claim 18 adhering to the matrix C -d’) optionally converting the ammonium salt contained in the prostheses coming from step (c’) into a hyaluronic acid derivative selected from those as defined in claims 12-17 5 -e) freeze drying the product coming from (d’)

28. A process for preparing a three-dimensional prosthesis according to claim 2, wherein the matrix A is A2 or it is the product of step (c) or (d) of the process according to claim 26 and is adhered to matrix C, comprising the following steps: 10 -a”) applying a thin layer of a solution of a hyaluronic acid derivative in a suitable aqueous or organic solvent, said hyaluronic acid derivative being selected from those as defined in claims 12-17 -b”) applying to the freeze dried product coming from step (a”) a non woven tissue comprising a hyaluronic acid derivative 15 -c”) freeze-drying the product coming from step (b”)

29. A process for preparing a three-dimensional prosthesis according to claim 1 containing at least one porous matrix consisting of a hyaluronic acid derivative, comprising the following steps: a”‘) pouring an aqueous solution of a quaternary ammonium salt as defined in 20 claim 18 into a mould having the shape of the body part to be reconstructed b”‘) freeze drying the aqueous solution in the mould c”‘) detaching the freeze dried product from the mould and converting the freeze dried ammonium salts into at least one hyaluronic acid derivative selected from those as defined in claims 12-17 25 d’) freeze drying the product, coming from the preceding step, in the mould

AU46115/99A
1998-06-17
1999-06-16
Three-dimensional prostheses containing hyaluronic acid derivatives

Expired

AU761325B2
(en)

Applications Claiming Priority (3)

Application Number
Priority Date
Filing Date
Title

IT98PD000149A

ITPD980149A1
(en)

1998-06-17
1998-06-17

THREE-DIMENSIONAL PROSTHESES INCLUDING HYALURONIC ACID DERIVATIVES TO REPAIR OR REBUILD DAMAGED TISSUES AND PROCESS FOR THE

ITPD98A00149

1998-06-17

PCT/EP1999/004167

WO1999065534A1
(en)

1998-06-17
1999-06-16
Three-dimensional prostheses containing hyaluronic acid derivatives

Publications (2)

Publication Number
Publication Date

AU4611599A
true

AU4611599A
(en)

2000-01-05

AU761325B2

AU761325B2
(en)

2003-06-05

Family
ID=11392251
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU46115/99A
Expired

AU761325B2
(en)

1998-06-17
1999-06-16
Three-dimensional prostheses containing hyaluronic acid derivatives

Country Status (10)

Country
Link

US
(1)

US6642213B1
(en)

EP
(2)

EP1087797B1
(en)

JP
(2)

JP4856309B2
(en)

AT
(1)

ATE492304T1
(en)

AU
(1)

AU761325B2
(en)

CA
(1)

CA2335023C
(en)

DE
(2)

DE69941151D1
(en)

ES
(2)

ES2358197T3
(en)

IT
(1)

ITPD980149A1
(en)

WO
(1)

WO1999065534A1
(en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

JP3848164B2
(en)

2000-05-03
2006-11-22
フィディア・アドバンスト・バイオポリマーズ・ソシエタ・ア・レスポンサビリタ・リミタータ

Biomaterial consisting of preadipocytes for soft tissue repair

EP1296809B1
(en)

2000-07-04
2004-10-13
3di GmbH
Method for the production of faithfully-reproduced medical implants and epiprostheses and said implants and epiprostheses

PL361732A1
(en)

2000-12-28
2004-10-04
Fidia Advanced Biopolymers S.R.L.
Use of a biological material containing three-dimensional scaffolds of hyaluronic acid derivatives for the preparation of implants in arthroscopy and kit for instruments for implanting said biological material by arthroscopy

ITPD20010032A1
(en)

2001-02-09
2002-08-09
Fidia Advanced Biopolymers Srl

ENGINEERED GRAFTES FOR THE REPAIR OF OSTEOCONDRAL DEFECTS

KR20040017842A
(en)

2001-07-30
2004-02-27
가부시키가이샤 재팬 티슈 엔지니어링
Tissue regenerating base material, implanting material and method of producing the same

US7662954B2
(en)

2001-10-30
2010-02-16
Colorado State University Research Foundation
Outer layer having entanglement of hydrophobic polymer host and hydrophilic polymer guest

DE10328816A1
(en)

2003-06-21
2005-01-05
Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin

Implantable stimulation electrode with a coating to increase tissue compatibility

DE10328815A1
(en)

2003-06-21
2005-01-05
Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin

Coating system for implants to increase tissue compatibility

ITPD20040053A1
(en)

2004-02-27
2004-05-27
Fidia Advanced Biopolymers Srl

BIOMATERIALS CONSTITUTED FROM HYALURONIC ACID DERIVATIVES AS A NEW CARE THERAPY FOR THE PROTECTION AND REPAIR OF DAMAGED ARTICULAR CARTILAGE FOR OSTEOARTHROSIS

ITPD20040312A1
(en)

2004-12-15
2005-03-15
Fidia Advanced Biopolymers Srl

PROSTHESIS AND SUPPORT FOR REPLACEMENT, REPAIR, REGENERATION OF THE MENISCUS

US7767656B2
(en)

2005-04-25
2010-08-03
Molly S Shoichet
Blends of temperature sensitive and anionic polymers for drug delivery

AU2006286158A1
(en)

2005-09-02
2007-03-08
Colbar Lifescience Ltd.
Cross-linked polysaccharide and protein matrices and methods for their preparation

JP5088864B2
(en)

2007-03-16
2012-12-05
オリンパス株式会社

Biological tissue filling material and manufacturing method thereof

KR100947553B1
(en)

2008-02-14
2010-03-12
주식회사 바이오랜드
Biological implantation material and method for preparing same

JP5758797B2
(en)

2008-04-04
2015-08-05
ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション

Alkylated semi-synthetic glycosaminoglycan ethers and methods for their production and use

WO2011072399A1
(en)

2009-12-18
2011-06-23
The Governing Council Of The University Of Toronto
Injectable polymer composition for use as a cell delivery vehicle

AU2012230822A1
(en)

2011-03-23
2013-11-07
University Of Utah Research Foundation
Methods for treating or preventing urological inflammation

US9782345B2
(en)

2013-10-17
2017-10-10
Jade Therapeutics, Inc.
Ocular composition and method

WO2018053111A1
(en)

2016-09-15
2018-03-22
University Of Utah Research Foundation
In situ gelling compositions for the treatment or prevention of inflammation and tissue damage

CN108752487A
(en)

2018-04-16
2018-11-06
江苏大学
A method of detaching fungi exocellular polysaccharide using three-phase system

EP4255517A1
(en)

2020-12-02
2023-10-11
Anika Therapeutics, Inc.
Bioabsorbable textiles and methods for joint function restoration

Family Cites Families (23)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4340091A
(en)

1975-05-07
1982-07-20
Albany International Corp.
Elastomeric sheet materials for heart valve and other prosthetic implants

SE8501022L
(en)

1985-03-01
1986-09-02
Pharmacia Ab

FORMAT CREATES AND PROCEDURES FOR ITS PREPARATION

US4851521A
(en)

1985-07-08
1989-07-25
Fidia, S.P.A.
Esters of hyaluronic acid

IT1198449B
(en)

1986-10-13
1988-12-21
F I D I Farmaceutici Italiani

ESTERS OF POLYVALENT ALCOHOLS OF HYALURONIC ACID

US5736372A
(en)

1986-11-20
1998-04-07
Massachusetts Institute Of Technology
Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure

US5306311A
(en)

1987-07-20
1994-04-26
Regen Corporation
Prosthetic articular cartilage

US5681353A
(en)

1987-07-20
1997-10-28
Regen Biologics, Inc.
Meniscal augmentation device

IT1219587B
(en)

1988-05-13
1990-05-18
Fidia Farmaceutici

SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES

JP2706476B2
(en)

1988-07-20
1998-01-28
住友大阪セメント株式会社

Artificial pelvis

IT1248934B
(en)

1990-06-01
1995-02-11
Fidia Spa

BIOCOMPATIBLE PERFORATED MEMBRANES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS A SUPPORT FOR THE IN VITRO GROWTH OF EPITHELIAL CELLS, ARTIFICIAL LEATHER THUS OBTAINED AND THEIR USE IN LEATHER TRANSPLANTS

AU636544B1
(en)

1991-11-27
1993-04-29
Lignyte Co., Ltd.
Water insoluble biocompatible hyaluronic acid polyion complex and method of making the same

IT1254704B
(en)

1991-12-18
1995-10-09
Mini Ricerca Scient Tecnolog

NON-WOVEN FABRIC ESSENTIALLY CONSTITUTED FROM DERIVATIVES OF HYALURONIC ACID

JPH06197948A
(en)

1993-01-05
1994-07-19
Terumo Corp
Artificial prosthesis

ITPD940054A1
(en)

1994-03-23
1995-09-23
Fidia Advanced Biopolymers Srl

SULPHATED POLYSACCHARIDES

US5632745A
(en)

1995-02-07
1997-05-27
R&D Biologicals, Inc.
Surgical implantation of cartilage repair unit

TW369414B
(en)

1994-09-30
1999-09-11
Yamanouchi Pharma Co Ltd
Bone formation transplant

JP3799626B2
(en)

1995-04-25
2006-07-19
有限会社ナイセム

Cardiovascular repair material and method for producing the same

IT1281870B1
(en)

1995-04-27
1998-03-03
Fidia Advanced Biopolymers Srl

HUMAN ARTIFICIAL SKIN MADE UP OF BIOCOMPATIBLE MATERIALS BASED ON HYALURONIC ACID DERIVATIVES

IT1281877B1
(en)

1995-05-10
1998-03-03
Fidia Advanced Biopolymers Srl
Heavy metal salts of succinyl derivatives of hyaluronic acid and their use as potential therapeutic agents

IT1282207B1
(en)

1995-11-20
1998-03-16
Fidia Advanced Biopolymers Srl

HUMAN BONE MARROW STEM CELL CULTURE SYSTEMS IN THREE-DIMENSIONAL MATRIXES CONSISTING OF HYALURONIC ACID ESTERS

JP3358048B2
(en)

1995-12-29
2002-12-16
タキロン株式会社

Shell for prosthesis and method for producing the same

DE69809892T2
(en)

1997-04-04
2003-08-28
Fidia Advanced Biopolymers Srl

N-SULFATED HYALURONIC ACID COMPOUNDS, THEIR DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF

IT1293484B1
(en)

1997-06-11
1999-03-01
Fidia Advanced Biopolymers Srl

BIOLOGICAL MATERIAL INCLUDING AN EFFICIENT CELL CULTURE AND A BIOCOMPATIBLE AND BIODEGRADABLE THREE-DIMENSIONAL MATRIX

1998

1998-06-17
IT
IT98PD000149A
patent/ITPD980149A1/en
unknown

1999

1999-06-16
CA
CA2335023A
patent/CA2335023C/en
not_active
Expired – Lifetime

1999-06-16
AT
AT05106820T
patent/ATE492304T1/en
not_active
IP Right Cessation

1999-06-16
DE
DE69941151T
patent/DE69941151D1/en
not_active
Expired – Lifetime

1999-06-16
ES
ES05106820T
patent/ES2358197T3/en
not_active
Expired – Lifetime

1999-06-16
DE
DE69943067T
patent/DE69943067D1/en
not_active
Expired – Lifetime

1999-06-16
AU
AU46115/99A
patent/AU761325B2/en
not_active
Expired

1999-06-16
ES
ES99929241T
patent/ES2329430T3/en
not_active
Expired – Lifetime

1999-06-16
WO
PCT/EP1999/004167
patent/WO1999065534A1/en
active
IP Right Grant

1999-06-16
EP
EP99929241A
patent/EP1087797B1/en
not_active
Expired – Lifetime

1999-06-16
JP
JP2000554411A
patent/JP4856309B2/en
not_active
Expired – Lifetime

1999-06-16
EP
EP05106820A
patent/EP1609493B1/en
not_active
Expired – Lifetime

1999-06-16
US
US09/719,200
patent/US6642213B1/en
not_active
Expired – Lifetime

2011

2011-07-15
JP
JP2011157097A
patent/JP2011212464A/en
active
Pending

Also Published As

Publication number
Publication date

ATE492304T1
(en)

2011-01-15

JP2002518101A
(en)

2002-06-25

JP2011212464A
(en)

2011-10-27

ITPD980149A1
(en)

1999-12-17

EP1087797B1
(en)

2009-07-22

EP1609493B1
(en)

2010-12-22

EP1087797A1
(en)

2001-04-04

CA2335023C
(en)

2012-05-22

DE69943067D1
(en)

2011-02-03

EP1609493A1
(en)

2005-12-28

JP4856309B2
(en)

2012-01-18

ES2358197T3
(en)

2011-05-06

CA2335023A1
(en)

1999-12-23

ES2329430T3
(en)

2009-11-25

DE69941151D1
(en)

2009-09-03

WO1999065534A1
(en)

1999-12-23

US6642213B1
(en)

2003-11-04

AU761325B2
(en)

2003-06-05

Contact information